OCS Oculis Holding AG
Price Chart
Executive Summary
Oculis announced the first patient randomized in PREDICT-1, a genotype-based registrational trial for Licaminlimab in dry eye disease. This is a key milestone for a first-in-class precision medicine approach targeting TNFR1 genotype patients, but the trial is early-stage with no efficacy data yet. The stock has historically shown poor T+20 performance on prior reports, suggesting limited near-term catalyst impact.
Actionable Insight
Monitor for interim or top-line data from PREDICT-1, which could serve as a significant catalyst. The precision medicine angle differentiates Licaminlimab, but the stock's historical T+20 performance on prior reports has been poor (avg -19.29%), suggesting limited near-term upside from this milestone alone. Consider waiting for efficacy readouts before taking a position.
Key Facts
- First patient randomized in PREDICT-1, a registrational trial for Licaminlimab in dry eye disease (DED).
- Trial plans to enroll ~160 patients, with ~2/3 having a specific TNFR1 genotype.
- Primary endpoint: change from baseline to Day 29 in global ocular discomfort severity score in TNFR1 genotype patients.
- Phase 2 data showed 5- to 7-fold more pronounced treatment effect in patients with TNFR1 variant.
- Only 13% of DED patients experience sustained relief with current treatments; 85-90% discontinue within 6 months.
- Licaminlimab is an investigational drug with no regulatory approval for commercial use.
Financial Impact
No financial data disclosed; trial is early-stage with no revenue impact expected for years.
Risk Factors
- Clinical trial failure: PREDICT-1 may not meet primary endpoint.
- Regulatory risk: Licaminlimab has not received approval for any indication.
- Competition: DED market has existing therapies and other pipeline candidates.
- Historical poor T+20 performance on OCS reports suggests limited near-term catalyst impact.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3308587 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
9d ago
|
Press Release
| $11.00 $11.30 | ▲ +2.73% | ▲ +2.29% | $11.22 (+2.00%) |
|
Jun 9, 2026
11d ago
|
Press Release
| $10.98 $11.61 | ▲ +5.74% | ▲ +3.33% | $11.22 (+2.19%) |
|
May 29, 2026
22d ago
|
Press Release
| $22.71 $11.21 | ▲ +50.63% | ▲ +48.10% | $11.22 (+50.58%) |
|
May 11, 2026
5w ago
|
Press Release
| $30.41 $28.07 | ▼ −7.69% | ▼ −7.77% | $11.22 (−63.10%) |
|
May 11, 2026
5w ago
|
Press Release
| $30.41 $28.07 | ▼ −7.69% | ▼ −7.77% | $11.22 (−63.10%) |
|
May 7, 2026
6w ago
|
Press Release
| $31.09 $31.37 | ▲ +0.90% | ▼ −0.60% | $11.22 (−63.91%) |
|
May 5, 2026
6w ago
|
Press Release
| $27.75 $30.41 | ▲ +9.59% | ▲ +7.60% | $11.22 (−59.57%) |
|
Apr 20, 2026
8w ago
|
Press Release
| $28.61 $27.12 | ▼ −5.21% | ▼ −6.12% | $11.22 (−60.78%) |
|
Mar 16, 2026
13w ago
|
Press Release
| $26.02 $24.60 | ▼ −5.46% | ▼ −3.42% | $11.22 (−56.88%) |
|
Mar 3, 2026
15w ago
|
Press Release
| $27.72 $27.28 | ▼ −1.59% | ▼ −0.25% | $11.22 (−59.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access